- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03737760
"Mind in Motion": Multimodal Imaging of Brain Activity to Investigate Walking and Mobility Decline in Older Adults
Multimodal Imaging of Brain Activity to Investigate Walking and Mobility Decline in Older Adults
Study Overview
Status
Detailed Description
This study is a longitudinal, prospective cohort study with a follow-up period of 1.2 - 3.5 years, dependent on when the participant enrolls. Participants will be assessed at baseline, and then every six months for 3.5 years or until the study ends, whichever comes first.
The investigators plan to enroll 200 community-dwelling men and women age 70+ years.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: David J Clark, ScD
- Phone Number: 105244 352-376-1611
- Email: davidclark@ufl.edu
Study Contact Backup
- Name: Todd Manini, PhD
- Phone Number: 352-273-5919
- Email: tmanini@ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria for Older Adults:
- Community dwelling men and women 65+ years old, or 60+ for individuals who belong to underrepresented racial or ethnic groups;
- Short Physical Performance Battery (SPPB) <10 (45% of the sample will have an SPPB < 8) for moderate to low functioning older adults; SPPB>=10 for high functioning older adults
- Able to complete the 400 m walk test within 15 minutes without sitting or the help of another person and without a walker, a cane is allowed
- Willingness to undergo all testing procedures
- English speaking
- Willingness to be enrolled for 1.25 to 3.5 years, depending on enrollment date.
Inclusion Criteria for Young Adults:
- Healthy men and women aged 20-40 years old
- Willingness to undergo all testing procedures
- English speaking
Exclusion Criteria for all participants:
- Significant medical event requiring hospitalization in the past 6 months that has the potential to contaminate data being collected (fracture, hospitalization etc.);
- Severe visual impairment or corrected visual acuity less than 20/40, which would preclude completion of the assessments;
- Not meeting MRI eligibility (e.g. metal implants, pacemaker, etc.)
- Clinically diagnosed vestibular dysfunction;
- Unwilling or unable to do an over-ground version of the uneven terrain task without assistive device;
- Develops chest pain or severe shortness of breath during physical stress;
- Stroke or other brain injury within the past three years;
- Current presence of motor deficits caused by a stroke or other brain injury;
- Diagnosis of dementia or taking cholinesterase inhibitors (Aricept, Exelon, Razadyne, Namenda, or Namzaric);
- Any major ADL disability (unable to feed, dress, bath, use the toilet, or transfer);
- Report of severe lower extremity pain that significantly limits mobility;
- Diagnosis or treatment for rheumatoid arthritis;
- Lives in a nursing home; persons living in assisted or independent housing will not be excluded;
- Receiving physical therapy for gait, balance, or other lower extremity training;
- Known neuromuscular disorder or overt neurological disease (e.g. Multiple Sclerosis, Rhabdomyolysis, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, Parkinson's Disease, ALS etc.)
- Unable to communicate because of severe hearing loss or speech disorder;
- Planned surgical procedure or hospitalization in the next 12 months (e.g., joint replacement, CABG);
- Severe pulmonary disease, requiring the use of supplemental oxygen;
- Terminal illness, as determined by a physician;
- Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina;
- Is planning to move out of the area in next year or leave the area for >6 mos during follow-up;
Other significant conditions that would impact safety and/or compliance to the protocol (e.g. renal failure on hemodialysis, psychiatric disorder-bipolar, schizophrenia, excessive alcohol intake etc.);
-Actively enrolled in an intervention study
- Use of walker or wheel chair;
- Artificial hair covering the scalp such as a wig or toupee
- Failure to provide informed consent;
- Transaminases >twice upper limit of normal;
- Hemoglobin <10 g/dL;
Investigator discretion based on safety or compliance concerns
-Temporary exclusion criteria (participant may be eligible if these issues are resolved in the future):
- Abnormalities in blood chemistry parameters as defined above;
- Severe hypertension, e.g., SBP > 200, DBP > 110 mmHg;
- Uncontrolled diabetes or hyperglycemia (fasting blood glucose > 126 mg/dl or hemoglobin A1C > 6.5%)
- Other temporary events that would influence participation (e.g. episodic health event, sick spouse, bereavement, or recent move);
- Other conditions identified with medical history at enrollment that places the participant at risk for participation.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Older Adults
Community-dwelling men and women age 70+ years
|
Younger Adults
Healthy young adults, age 20-40 years for baseline assessments only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain activity during walking
Time Frame: Baseline up to 42 months
|
Changes in brain activity during complex walking (uneven terrain), assessed longitudinally for up to 3.5 years
|
Baseline up to 42 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Clark, ScD, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IRB201802227-N
- P30AG059297 (U.S. NIH Grant/Contract)
- 1U01AG061389-01 (U.S. NIH Grant/Contract)
- OCR19439 (Other Identifier: University of Florida)
- IRB201900001 (Other Identifier: UF IRB-01 SubStudy)
- IRB202201585 (Other Identifier: UF IRB-01 SubStudy)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Effect of Age-related Changes in the Brain on Walking Ability
-
Medical University of SilesiaCompletedChanges in Blood Flow to the Brain | Changes Depending on the Form of WalkingPoland
-
Tianjin Medical University General HospitalShehzaad Joomye; Haiyun Wang; Donglai YanUnknownThe Intraoperative Effect of Dexmedetomidine on Cisatracurium Infusion Consumption and Its Recovery Index. | Effect of Dexmedetomidine on Sufentanil Consumption. | Quantitative Analysis of Cisatracurium Infusion Requirements, Sufentanil Consumption and Recovery Index in Different Age...China
-
Neurocrine BiosciencesCompletedEffect of Ketoconazole on the PK of NBI-98854 in Healthy SubjectsUnited States
-
Tampa General HospitalWithdrawnEffect of Protocolized Sedation on Days of Mechanical Ventilation in the ICUUnited States
-
University Health Network, TorontoCompletedThe Study Focuses on the Effect of a New Supraglottic Airway With Built-in Cuff Pressure Indicator on Postoperative Pharyngolaryngeal Adverse EventsCanada
-
Xiaomei ZhangUnknownThe Effect of Iodine and BPA on AITD in Reproduction WomenChina
-
OSF Healthcare SystemUniversity of Illinois College of Medicine at PeoriaCompletedthe Focus of the Clinical Trial is on the Brain Temperatures in Normal Human SubjectsUnited States
-
The Touro College and University SystemUniversity of Vienna; Osato Research Institute; University of Mauritius; Mauritius... and other collaboratorsCompletedAssess the Effect of Green Tea on Diabetes | Assess the Effect of Fermented Papaya Pretration on Diabetes | Effects of Green Tea and FPP on C-reactive Proteins | Effects of Green Tea and FPP of Lipid Profiles in Diabetes | Effect of Green Tea and FPP on Atheroma FormationAustria, Mauritius, United States
-
Ain Shams UniversityUnknownEffect of Meperidine or Drotaverine on Effacement and Dilatation of the Cervix During Labor in Full Term PrimigravidaeEgypt
-
Bursa Yüksek İhtisas Education and Research HospitalCompletedThe Aim of This Research is to Investigate the Effect of Prolotherapy on Quality of Life and Painkiller Use in Patients With Chronic Knee PainTurkey